GlycoFi is a bio tech firm that develops bio-therapeutics based on the glycan optimization technology.
Business Model:
Revenue: $0
Employees: 51-500
GlycoFi Inc. was acquired by
Merck Sharp &a; Dohme Sweden AB.
The acquisition happend on 2006-05-09.
Details of the transaction were not public
Address:
City: Hanover
State: New Hampshire
Zip:
Country: United States
GlycoFi is a biotech firm that develops biotherapeutics based on the glycan optimization technology. The firm aims to develop its own pipeline of therapeutic proteins and team with other drug-makers to develop products. GlycoFi has developed a protein manufacturing process using yeast-based glycolysation where the resulting proteins can be used in drug development. GlycoFi was incorporated in 2000 and is based in Lebanon, New Hampshire. As of June 6, 2006, GlycoFi, Inc. operates as a subsidiary of Merck &a; Co. Inc.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 10/2005 | Series C | 9 | $11M |
Borealis Ventures Boston Millennia Partners Eli Lilly Fletcher Spaght, Inc. International Biotechnology Trust Peninsula Capital Polaris Partners SV Health Investors Village Ventures Borealis Ventures Boston Millennia Partners Eli Lilly Fletcher Spaght, Inc. International Biotechnology Trust Peninsula Capital Polaris Partners SV Health Investors Village Ventures |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|